These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25022794)

  • 1. Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis.
    Landi D; Vollaro S; Pellegrino G; Mulas D; Ghazaryan A; Falato E; Pasqualetti P; Rossini PM; Filippi MM
    Clin Neurophysiol; 2015 Jan; 126(1):165-9. PubMed ID: 25022794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
    Ayache SS; Créange A; Farhat WH; Zouari HG; Mylius V; Ahdab R; Abdellaoui M; Lefaucheur JP
    Eur J Neurol; 2014 Apr; 21(4):630-6. PubMed ID: 24471453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
    Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
    Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaco-transcranial magnetic stimulation studies of motor excitability.
    Ziemann U
    Handb Clin Neurol; 2013; 116():387-97. PubMed ID: 24112911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of fingolimod in clinical practice.
    Thomas K; Ziemssen T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

  • 17. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis.
    Conte A; Lenzi D; Frasca V; Gilio F; Giacomelli E; Gabriele M; Bettolo CM; Iacovelli E; Pantano P; Pozzilli C; Inghilleri M
    J Neurol; 2009 Jun; 256(6):933-8. PubMed ID: 19252788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
    Rabasseda X
    Drugs Today (Barc); 2010 Jul; 46 Suppl D():1-14. PubMed ID: 20820453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.